Plasmodium berghei is resistant to aryl amino acetamides that inhibit P. falciparum growth by targeting the phospholipid transfer protein Pf START1.
Rattachement africain : au. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
In a previous screen for compounds that inhibit Plasmodium falciparum merozoite invasion of red blood cells, we identified the Medicines for Malaria Venture compound MMV006833. This compound inhibits Pf START1, a protein implicated in the expansion of the nascent parasitophorous vacuole membrane following invasion, to accommodate the developing ring-stage parasite. Live-cell lattice light-sheet microscopy of invading merozoites revealed that mNeonGreen-tagged Pf START1 is released from structures within the merozoite into the nascent parasitophorous vacuole approximately 109 seconds after invasion. Expansion microscopy of Pf START1-HA merozoites further showed that these punctate Pf START1-containing structures do not colocalise with known secretory organelles (rhoptries, micronemes and dense granules). Although analogues of MMV006833 are highly potent against P. falciparum , they were previously found to be ineffective against P. berghei parasites in the mouse malaria model. Here, we demonstrate that Pb START1 is highly resistant to MMV006833 and its analogues when expressed in P. falciparum , indicating that structural differences between the orthologous proteins reduce inhibitor potency. The crystal structure of Pf START1 in complex with WEHI-991 revealed the molecular basis for inhibition and provided a structural explanation for the reduced potency of this family of compounds against P. berghei . To sensitise P. berghei parasites to MMV006833 analogues, the parasites were engineered to express Pf START1; however, these chimeric parasites remained insensitive to the compounds. This suggests that factors beyond target engagement, such as compound half-life or bioavailability, contribute to the lack of efficacy observed in the mouse malaria model.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- <i>Plasmodium berghei</i> is resistant to aryl amino acetamides that inhibit <i>P. falciparum</i> growth by targeting the phospholipid transfer protein <i>Pf</i> START1.
- Date Crossref
- 24/09/2026
- Éditeur
- openRxiv
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Burnet Institute pays non établi dans la noticeOrganisation à but non lucratif
-
Deakin University pays non établi dans la noticeUniversité ou école supérieure
-
Walter and Eliza Hall Institute of Medical Research pays non établi dans la noticeOrganisation à but non lucratif
-
The University of Adelaide pays non établi dans la noticeUniversité ou école supérieure
Burnet Institute, Deakin University et Walter and Eliza Hall Institute of Medical Research, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.